Essential medicines and health products

Malaysia a country case study: good governance and preventing corruption

Draft 8 November 2010

Malaysia joined WHO's Good Governance for Medicines Programme (GGM) in 2004. It was among the first four Asian countries to join the programme - the others being Laos, Philippines and Thailand.


Malaysia had a good basis for the programme: the country already had a strong pharmaceutical system, and a robust National Integrity Plan. Other governmental initiatives are under way to increase transparency specifically in the health system. Meanwhile there is strong commitment to the Government Transformation Programme unveiled in January 2010 and the national mission for achieving Vision 2020 - helping Malaysia achieve the status of a fully developed nation


The programme is now fully institutionalized within the Malaysian Pharmaceutical Services Division (PSD). Key steps included developing a GGM framework within the National Integrity Plan, and establishing a steering committee and taskforce. Taskforce members include senior officials from the Pharmaceutical Services Division and academics. The Programme has developed awareness raising activities including seminars, workshops and awareness campaigns; issued a series of brochures on integrity for all public servants, and established an audit value management system.


The number of public servants caught in corrupt activities has decreased in the past three years.

The number of public servants caught in corrupt activities has decreased in the past three years.

  • Online services, including registration of medicines
  • Greater availability of information available on the Ministry of Health website, such as the list of essential medicines and registration forms for medicines
  • Implementation of conflict of interest policy for various committee members, enforced since 2008
  • Posting results of tenders on the web
  • Inclusion of transparency issues on the agenda of hospital drug committee meetings.